Group 1: Macroeconomic Focus - "Stabilizing prices" is a key focus of macroeconomic policy in 2025, with the CPI growth target set at around 2%, the first time below 3% since 2003[3] - The GDP deflator index has been under pressure since 2023, indicating a divergence in economic volume and price, which has negatively impacted consumer confidence and corporate profits[3] - The new price governance mechanism aims to address the low price environment and stimulate economic vitality through supply-side structural reforms[3] Group 2: Price Mechanism Reform - The current price mechanism reform echoes the 2015 initiative, both addressing insufficient capacity utilization and downward price pressure in the economy[3] - The 2025 reform emphasizes market price regulation and aims to correct market failures, particularly in sectors experiencing "price wars" and "involution" competition[4] - Key areas of focus include energy pricing reforms, particularly in new energy and carbon pricing, and adjustments in public service pricing to alleviate fiscal pressure[4] Group 3: Supply-Side Structural Reform - The supply-side structural reform strategy has become clearer since 2024, focusing on phasing out subsidies and enhancing market price mechanisms[4] - The reform aims to accelerate the exit of inefficient, high-energy-consuming production capacities through energy consumption control measures[4] - The photovoltaic industry and high-energy raw material sectors are expected to see price recoveries as a result of these reforms, leading to a reasonable rebound in prices[4]

海外宏观 2025 年 4 月 2 日 宏观深度报告 从德国财政转向看欧洲"觉醒" 证券分析师 | 钟正生 | 投资咨询资格编号 | | --- | --- | | | S1060520090001 | | | ZHONGZHENGSHENG934@pingan.com.cn | | 张璐 | 投资咨询资格编号 | | | S1060522100001 | | | ZHANGLU150@pingan.com.cn | | 范城恺 | 投资咨询资格编号 | | | S1060523010001 | | | FANCHENGKAI146@pingan.com.cn | 平安观点： 宏 观 报 告 宏 观 深 度 报 告 证 券 研 究 报 告 德国财政：打破紧缩教条。德国新政党推出新的财政计划，有三大核心内 容：1、打破国防开支约束，超过 GDP 1%的国防开支将排除在"债务刹 车"计算范围外。2、放宽地方债务限制，允许州举债至 GDP 的 0.35%。 3、设立 5000 亿预算外专项基金，将在 10 年内使用。初步估算，德国新 的财政计划之下，每年可能增加 1000 亿欧元的支出（占 GDP 的 2%左 右） ...

Investment Rating - The report maintains an "Outperform" rating for the power equipment and new energy sector [1]. Core Insights - In the first two months of 2025, China's inverter export value reached 7.7 billion yuan, a slight increase of 6.5% year-on-year. Asia has overtaken Europe as the largest market for inverter exports, with significant growth in South Asia and the Middle East [2][13][16]. Summary by Sections Inverter Monthly Export Overview - The total inverter export value for January-February 2025 was 7.7 billion yuan, with Asia, Europe, and Latin America being the top three markets, accounting for 38%, 32%, and 13% of exports respectively [13][16]. Asia: Export Growth with Strong Performance in South Asia and the Middle East - In January-February 2025, inverter exports to Asia amounted to 2.87 billion yuan, a year-on-year increase of 31%. Key markets included India and Pakistan, with exports to India growing by 74% and to Pakistan by 63% [2][28][36]. Europe: Overall Decline in Exports - Exports to Europe totaled 2.46 billion yuan, a decrease of 11% year-on-year. The Netherlands and Germany were the main markets, with exports declining by 4% and 14% respectively [54][55]. Latin America & Africa: Mixed Performance - Exports to Latin America were 1.02 billion yuan, down 3% year-on-year, with Brazil being the largest market. In contrast, exports to Africa increased by 26%, totaling 660 million yuan, with South Africa and Nigeria showing significant growth [2][16][54]. Investment Recommendations - The report recommends focusing on leading companies in the overseas large storage and emerging market household storage sectors, highlighting companies like Sungrow Power Supply, Deye Technology, and Shuneng Electric as key players [2][9].

医药 2025 年 04 月 02 日 科兴制药(688136.SH) 出海业务有望保持高增长，创新药平台价值静待重估 推荐（维持） 股价：28.13 元 主要数据 | 行业 | 医药 | | --- | --- | | 公司网址 | www.kexing.com | | 大股东/持股 | 深圳科益医药控股有限公司/66.01% | | 实际控制人 | 邓学勤 | | 总股本(百万股) | 200 | | 流通 A 股(百万股) | 200 | | 流通 B/H 股(百万股) | | | 总市值（亿元） | 56 | | 流通 A 股市值(亿元) | 56 | | 每股净资产(元) | 8.09 | | 资产负债率(%) | 46.0 | 行情走势图 相关研究报告 【平安证券】科兴制药（688136.SH）*深度报告*多国 GMP验厂节奏符合预期，白紫出海欧盟确定性较强*推 荐20240509 证券分析师 | 叶寅 | 投资咨询资格编号 | | --- | --- | | | S1060514100001 | | | BOT335 | | | YEYIN757@pingan.com.cn | | 研究助理 | ...

Investment Rating - The report maintains a "Recommended" investment rating for Vanke A (000002.SZ) with a current stock price of 7.11 yuan [1]. Core Views - The company reported a significant decline in revenue and net profit for 2024, with total revenue of 343.18 billion yuan, down 26.3% year-on-year, and a net loss of 49.48 billion yuan, down 506.8% year-on-year. The loss was slightly higher than the earnings forecast, and the company plans not to distribute dividends or issue bonus shares [5][8]. - The report highlights that the company's profitability is under pressure due to several factors, including a significant decrease in the settlement scale and gross profit margin of development business, which fell to 9.5%, leading to a comprehensive gross margin decline of 5.1 percentage points to 10.2% [8]. - The company is actively working on restructuring and risk mitigation strategies, focusing on core business operations and achieving stable sales and cash recovery [9]. Summary by Sections Financial Performance - In 2024, Vanke A's revenue is projected to be 343.18 billion yuan, with a year-on-year decline of 26.3%. The net profit is expected to be -49.48 billion yuan, reflecting a 506.8% decrease compared to the previous year [5][8]. - The gross margin is expected to remain at 10.2% for 2025, with a slight improvement to 11.3% by 2027 [7]. Operational Strategy - The company aims to deliver over 180,000 high-quality homes in 2024, achieving sales of 246.02 billion yuan, maintaining a sales recovery rate above 100% [8]. - Vanke A has completed 54 major asset transactions, totaling 25.9 billion yuan, and has optimized its capacity to recover over 10 billion yuan in cash [9]. Support from Shareholders - Since the end of 2023, major shareholders, including Shenzhen State-owned Assets and Shenzhen Metro Group, have provided substantial support to the company, assisting in the disposal of illiquid assets and facilitating financing [9]. - In early 2025, the major shareholder provided a total of 7 billion yuan in loans to meet the company's funding needs [9]. Future Earnings Projections - The report has adjusted the EPS forecast for 2025 to -0.80 yuan and for 2026 to -0.33 yuan, with a new projection for 2027 at 0.10 yuan. The current stock price corresponds to P/E ratios of -8.9 for 2025 and -21.7 for 2026 [9][10].

Investment Rating - The report maintains a "Strong Buy" rating for the company, indicating an expected stock performance that will exceed the market by more than 20% within the next six months [1][13]. Core Views - The company continues to invest heavily in research and development, maintaining a high level of R&D expenditure to enhance its competitive edge in the market [1][9]. - Despite a decline in revenue and net profit for 2024, the company is expected to recover in the following years, with projected growth in net profit from 2025 to 2027 [5][9]. Financial Performance Summary - In 2024, the company reported a revenue of 6,581 million yuan, a decrease of 9.62% year-on-year, and a net profit of 1,043 million yuan, down 26.75% year-on-year [5][8]. - The company's gross margin for 2024 was 72.0%, reflecting a decline of 2.8 percentage points compared to the previous year, while the net margin was 15.9% [8][11]. - R&D expenses for 2024 were 2,458 million yuan, accounting for 37.4% of total revenue, indicating a commitment to innovation despite financial pressures [8][11]. Revenue Breakdown - The company's revenue from wealth technology services was 1,430 million yuan, down 17.50% year-on-year, which was the primary contributor to the overall revenue decline [8]. - Other revenue segments, including operational and institutional technology services, also experienced declines, with revenues of 1,289 million yuan and 1,568 million yuan, down 10.24% and 8.38% respectively [8]. Future Projections - The company anticipates a recovery in revenue, projecting 7,048 million yuan in 2025, followed by 7,691 million yuan in 2026 and 8,469 million yuan in 2027, with respective growth rates of 7.1%, 9.1%, and 10.1% [7][11]. - Net profit is expected to rise to 1,211 million yuan in 2025, 1,449 million yuan in 2026, and 1,756 million yuan in 2027, with growth rates of 16.0%, 19.7%, and 21.1% respectively [7][11]. Strategic Focus - The company is deepening its strategic focus by enhancing its core product competitiveness, launching new platforms in asset management, brokerage, and wealth management [9]. - The introduction of innovative systems such as the UF3.0 brokerage core system and the O45 asset management platform is aimed at optimizing client services and improving risk management capabilities [9].

出海业务有望保持高增长，创新药平台价值静待重估 医药 2025 年 04 月 02 日 推荐（维持） 科兴制药(688136.SH) 股价：28.13 元 相关研究报告 主要数据 | 行业 | 医药 | | --- | --- | | 公司网址 | www.kexing.com | | 大股东/持股 | 深圳科益医药控股有限公司/66.01% | | 实际控制人 | 邓学勤 | | 总股本(百万股) | 200 | | 流通 A 股(百万股) | 200 | | 流通 B/H 股(百万股) | | | 总市值（亿元） | 56 | | 流通 A 股市值(亿元) | 56 | | 每股净资产(元) | 8.09 | | 资产负债率(%) | 46.0 | 行情走势图 【平安证券】科兴制药（688136.SH）*深度报告*多国 GMP验厂节奏符合预期，白紫出海欧盟确定性较强*推 荐20240509 证券分析师 | 叶寅 | 投资咨询资格编号 | | --- | --- | | | S1060514100001 | | | BOT335 | | | YEYIN757@pingan.com.cn | | 研究助理 | ...

Core Insights - The report highlights that the convertible bond market experienced a significant rally in Q1 2025, primarily driven by the technology sector and small-cap stocks, with convertible bonds outperforming expectations due to a 60% increase relative to their underlying stocks, surpassing the median elasticity of 40% [2][3][6] - The sustainability of the technology stock rally is a key focus for Q2, with expectations of potential consolidation after a rapid increase in stock prices, indicating that the current growth trend may not be over but could face short-term adjustments [2][25][69] Summary by Sections Market Performance - In Q1 2025, convertible bonds saw a broad increase, benefiting from the recovery in technology and small-cap styles, with a notable contribution from bond adjustments [2][6][9] - The overall performance of convertible bonds was characterized by a risk-return profile that remained balanced, with equity assets ending their weak phase [12][18] Investment Strategy - Timing: The report suggests that a good buying opportunity for TMT stocks will arise after a correction of approximately 15%, recommending gradual accumulation of positions as the market adjusts [4][66] - Selection: TMT and emerging cycle convertible bonds exhibit the highest elasticity in a growth market, with strong debt protection, suggesting that bonds priced below 110 yuan have significant investment value [4][69] Valuation and Risk Assessment - The valuation of convertible bonds is currently considered high, with future price movements largely dependent on the performance of underlying stocks, although a solid floor exists due to the significant decline in risk-free yields enhancing the bond floor [3][53][68] - The report indicates that the risk of credit downgrades or significant interest rate increases is currently low, with historical data showing that downgrades typically do not exceed 5% in a quarter [3][68] Focus Areas for Q2 - The technology sector is expected to continue its upward trend, although a phase of consolidation may occur, with historical patterns suggesting a typical adjustment period of around 15% after initial rapid gains [25][28][29] - The report emphasizes the importance of monitoring the performance of convertible bonds in relation to their underlying stocks, particularly in light of the recent market dynamics and potential adjustments [53][69]

Investment Rating - The investment rating for the company is "Recommended" [1] Core Views - The company has seen a significant increase in wind turbine orders, leading to an upward trend in profitability. The revenue for 2024 is projected to be 566.99 billion yuan, a year-on-year increase of 12.37%, with a net profit of 18.60 billion yuan, up 39.78% year-on-year [4][8] - The gross margin for wind turbine sales has improved significantly, contributing to the rapid growth in performance. The company expects further growth in wind turbine shipments and revenue in 2025 due to a substantial increase in orders [7][8] - The company is also experiencing stable growth in its power plant business and rapid development in wind power service operations, with service revenue reaching 55.1 billion yuan in 2024, a year-on-year increase of 29.26% [7][8] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 566.99 billion yuan, with a net profit of 18.60 billion yuan, and a diluted EPS of 0.44 yuan. The company plans to distribute a cash dividend of 1.40 yuan per 10 shares [4][8] - The projected revenues for 2025 and 2026 are 80.36 billion yuan and 90.01 billion yuan, respectively, with net profits expected to reach 30.00 billion yuan and 39.60 billion yuan [6][8] Business Segments - Wind turbine sales volume reached 16.05 GW in 2024, a year-on-year increase of 16.56%, with revenue from wind turbines and components at 389.2 billion yuan, up 18.17% year-on-year [7][8] - The company has a backlog of external wind turbine orders totaling 45.08 GW, a 51% increase year-on-year, with overseas orders accounting for 7.03 GW, also up approximately 50% [7][8] Market Outlook - The wind power industry is expected to remain favorable, with the company maintaining a strong competitive advantage in the wind turbine sector. The current stock price corresponds to dynamic P/E ratios of 12.5, 9.5, and 7.6 for the years 2025 to 2027 [8]

策略配置 2025 年 4 月 1 日 多元资产月报（2025 年 4 月） 国内交易逻辑回归基本面，关税政策搅动海外变局 证券分析师 | 魏伟 | 投资咨询资格编号 | | --- | --- | | | S1060513060001 | | | WEIWEI170@pingan.com.cn | | 陈骁 | 投资咨询资格编号 | | | S1060516070001 | | | CHENXIAO397@pingan.com.cn | | 刘璐 | 投资咨询资格编号 | | | S1060519060001 | | | LIULU979@pingan.com.cn | | 张亚婕 | 投资咨询资格编号 | | | S1060517110001 | | | ZHANGYAJIE976@pingan.com.cn | | 郭子睿 | 投资咨询资格编号 | | | S1060520070003 | | | GUOZIRUI807@pingan.com.cn | | 张君瑞 | 投资咨询资格编号 | | | S1060519080001 | | | ZHANGJUNRUI748@pingan.com.cn | | ...